Silexion Therapeutics Corp. announced the pricing of a public offering of $6.0 million.
The offering includes 1,500,000 ordinary shares, series A warrants, and series B warrants.
The public offering price is set at $4.00 per share.
Offering Details
1,500,000 ordinary shares, series A warrants, and series B warrants at $4.00 per share.
Proceeds Allocation
Intends to use net proceeds for pre-clinical studies and general corporate purposes.
Placement Agent
H.C. Wainwright & Co. is serving as the exclusive placement agent.
- The gross proceeds from the offering are expected to be $6.0 million before deduction of fees.
- The Company plans to advance its pre-clinical studies with the net proceeds.
- This offering indicates Silexion's commitment to developing innovative cancer treatments.
Silexion Therapeutics aims to further its advancements in oncology with the proceeds from this public offering.